Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...

Discover a groundbreaking study that may help detect Alzheimer's in its early stages. Learn about the link between blood ...

The funding will be used to move the ARGO-HT research platform into an FDA-cleared system to support the development of diagnostic tests.

Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...